New York State Teachers Retirement System Has $121.45 Million Stake in Gilead Sciences, Inc. $GILD

New York State Teachers Retirement System trimmed its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,094,150 shares of the biopharmaceutical company’s stock after selling 29,735 shares during the quarter. New York State Teachers Retirement System owned about 0.09% of Gilead Sciences worth $121,451,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of GILD. Brighton Jones LLC raised its holdings in Gilead Sciences by 20.6% during the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new stake in shares of Gilead Sciences during the fourth quarter worth about $215,000. Integrity Alliance LLC. acquired a new stake in shares of Gilead Sciences in the 1st quarter worth about $210,000. Focus Partners Wealth lifted its position in Gilead Sciences by 21.2% in the 1st quarter. Focus Partners Wealth now owns 142,666 shares of the biopharmaceutical company’s stock valued at $15,986,000 after acquiring an additional 24,930 shares in the last quarter. Finally, Modern Wealth Management LLC boosted its stake in Gilead Sciences by 24.4% during the 1st quarter. Modern Wealth Management LLC now owns 6,899 shares of the biopharmaceutical company’s stock valued at $773,000 after purchasing an additional 1,351 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Trading Up 0.4%

NASDAQ GILD opened at $121.10 on Friday. The business’s fifty day moving average is $123.27 and its 200-day moving average is $117.59. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market capitalization of $150.25 billion, a price-to-earnings ratio of 18.78, a PEG ratio of 0.64 and a beta of 0.33. Gilead Sciences, Inc. has a one year low of $88.57 and a one year high of $128.70.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the company posted $2.02 earnings per share. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 30th. Stockholders of record on Monday, December 15th were given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date of this dividend was Monday, December 15th. Gilead Sciences’s dividend payout ratio is currently 48.99%.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $125.86, for a total transaction of $3,524,080.00. Following the completion of the transaction, the insider owned 107,193 shares in the company, valued at $13,491,310.98. This trade represents a 20.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the completion of the transaction, the chief financial officer owned 153,503 shares of the company’s stock, valued at $18,727,366. The trade was a 1.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 136,257 shares of company stock worth $16,855,192 in the last three months. Corporate insiders own 0.27% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. BMO Capital Markets set a $135.00 price objective on Gilead Sciences in a research note on Tuesday, November 25th. Needham & Company LLC upped their price target on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a report on Thursday, November 13th. Truist Financial initiated coverage on Gilead Sciences in a research note on Monday, November 24th. They set a “buy” rating and a $140.00 price objective on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $135.00 target price on shares of Gilead Sciences in a research note on Friday, October 31st. Finally, TD Cowen increased their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $133.20.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.